Vaccinating Against Mutant RAS – Results from TG01 Phase I/II Trial

Time: 9:30 am
day: Day Two

Details:

• Results from 32-patient TG01 trial in resected pancreatic cancer

• Robust immune responses demonstrated against KRAS

• Overview of clinical and molecular outcomes

Speakers: